Preprint Brief Report Version 1 Preserved in Portico This version is not peer-reviewed

Histone H3K36 and H3K27 Modifiers and Readers as Prognostic Factors in Patients with Cancer—A Pancancer Analysis

Version 1 : Received: 25 September 2023 / Approved: 26 September 2023 / Online: 26 September 2023 (07:15:04 CEST)

How to cite: Ugwu, C.; Lin, P.; Laliotis, G. Histone H3K36 and H3K27 Modifiers and Readers as Prognostic Factors in Patients with Cancer—A Pancancer Analysis. Preprints 2023, 2023091740. https://doi.org/10.20944/preprints202309.1740.v1 Ugwu, C.; Lin, P.; Laliotis, G. Histone H3K36 and H3K27 Modifiers and Readers as Prognostic Factors in Patients with Cancer—A Pancancer Analysis. Preprints 2023, 2023091740. https://doi.org/10.20944/preprints202309.1740.v1

Abstract

Histone modifications, especially H3K27 and H3K36 methylations, are crucial for epigenetic regulation and are often dysregulated in cancer. In a comprehensive analysis of 11,194 patient samples across 32 cancer types, we identified significant genomic alterations in H3K27 and H3K36 modifiers, with the most common being in KDM6B, BRPF1, KDM6A, SETD2, and NSD1. Patients with these alterations also frequently exhibited mutations in genes like TP53 and PIK3CA. Moreover, the presence of these histone modifier alterations correlated with poorer overall survival, emphasizing their potential as both oncogenic drivers and prognostic markers in various cancers.

Keywords

Histone Modifiers; cancer; Genomics;

Subject

Biology and Life Sciences, Biology and Biotechnology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.